Axumin (fluciclovine 18F injection), for detecting biochemical recurrence of prostate cancer,
and NETSPOT (68Ga-dotatate injection), for localization of somatostatin receptor–positive …

Through its Priority Review mechanism, the US Food and Drug Administration (FDA)
recently approved 2 radiopharmaceutical products for use as diagnostic PET agents. The …

Significant advances continue in the development of cancerspecific molecular imaging
agents and modalities for diagnosing, staging, and treating various cancer types. For these …

Over the past year, SNMMI has implemented many new initiatives focused on putting the
patient first. As SNMMI president, I have worked with our dedicated leadership, volunteers …

My year as president of SNMMI has flown by. It has been a year of challenges, opportunities,
and, I'm pleased to say, accomplishments. The Therapy Center of Excellence (CoE) is up …

The outcomes of a 2011 Medical Imaging & Technology Alliance (MITA) conference helped
shape considerations about what might be the most appropriate pathways for the regulatory …

(FDAMA) required that PET drugs be prepared according to US Pharmacopeia (USP)
compounding standards and PET drug monographs until the Food and Drug Administration …

Recent advances in technology and discovery have led to a key role for nuclear medicine in
precision health and individualized patient care. As we enter this era of promise and growth …

“Radiopharmaceuticals for Positron Emission Tomography—Compounding,” as published in
the current version of the United States Pharmacopeia (USP)(1), provides extensive quality …

The approval of new imaging agents has slowed, much as for therapeutic drugs. Schering
and Amersham, for instance, each spent about $150 million a year for the period 1999–2004 …